Articles tagged with Antibodies
Patients treated with infliximab and adalimumab, a type of rheumatoid arthritis medication, are at an increased risk for developing herpes zoster (shingles). A significant association was found between treatment with these monoclonal anti-TNF-α antibodies and the development of shingles.
Scientists at Albert Einstein College of Medicine have developed radioimmunotherapy to target and destroy HIV-infected cells. The treatment, which uses antibodies attached to radioactive payloads, shows promise in laboratory and animal studies, and is currently being tested in pre-clinical trials.
Population immunity to measles was insufficient to interrupt transmission three years after a mass vaccination campaign in Zambia. Repeated mass vaccination campaigns are necessary to achieve high routine vaccine coverage and reduce measles deaths and illness.
Researchers at UCSF have identified a woman's immune system anomaly that may lead to breakthrough therapies for autoimmune diseases like rheumatoid arthritis and colitis. The discovery of antibodies blocking T-cell movement could result in more targeted treatments with lower risks of infections or tumors.
Researchers have discovered a unique antibody that blocks the S1P receptor on T cells, reducing their numbers in the bloodstream and potentially treating autoimmune disorders such as colitis, lupus, and rheumatoid arthritis. The study's findings suggest a new horizon for reversing disabling and often fatal conditions.
The Scripps Research team has developed a new technique to screen large antibody libraries against targets, enabling the acceleration of searches for new treatments against cancer and other diseases. This breakthrough allows for efficient access to the vast potential of synthetic antibodies.
Scientists have discovered a new mechanism by which the human immune system adapts to infections, involving 'cluster mutations' in antibody genes. This discovery fills a significant gap in our understanding of how we survive microbial invasions and may lead to new ways to prevent illnesses or make them less dangerous.
Researchers discovered that a 1966 RSV vaccine's defective antibodies failed to bind to the real virus, leading to severe disease. New findings could lead to the development of safer and more effective vaccines for RSV and other respiratory viruses.
A randomized clinical trial found that half-dose influenza vaccine produced similar antibody responses to full-dose vaccines in healthy adults. Women had a greater response to both doses, suggesting guidelines should consider sex as well as age. This study supports the validity of dose reduction strategies during vaccine shortages.
Researchers found that bavituximab, a PS-targeting antibody, can cure lethal virus infections in animal models of cytomegalovirus and Lassa fever. The drug showed potent anti-viral activity and may represent a new class of drugs for treating viral infections.
Researchers at MIT have developed a method to analyze single-cell responses to vaccination, providing a comprehensive picture of the immune system's ability to fight off infection. This breakthrough could lead to the development of new vaccines for diseases including HIV, fungal infections and antibiotic-resistant bacterial infections.
Researchers have developed a technique using soft lithography to create 'snapshots' of immune cell populations, offering insights into antibody diversity and potential for vaccine development. This innovation could lead to more effective diagnostic tools and personalized treatments.
A study found that a higher dose of flu vaccine boosts the immune response in people aged 65 and older, increasing antibody levels by 30-80% compared to the standard dose. This could lead to better protection against the flu for those most at risk.
The study found that the level of H. pylori IgG antibodies has limited value in diagnosing active peptic ulcer disease and does not show association with gastric mucosal morphology. A negative serology test result is reliable for excluding H. pylori infection, making it useful for screening purposes.
Sticky glue secreted by Staphylococcus aureus bacteria may hold the key to creating an effective vaccine against MRSA. Researchers have found that manipulating this natural compound can stimulate the right immune response, offering a potential solution to the growing problem of antibiotic-resistant infections.
A study of 50 healthy adult men found that black non-sensitized males had an average of 17.2% more HLA-sensitive B cells than white non-sensitized males, increasing their opportunity for antibody-mediated rejection. This increased number of B cells may be customized in treatments to lessen the likelihood of organ rejection.
Scientists have pinpointed the FCER1A gene as a major factor in allergic diseases, influencing IgE antibody production and leading to conditions like hay fever and asthma. The discovery has potential for guiding new drug development.
A virus that infects potatoes has been used to develop antibodies that can bind to the amyloid beta protein, a key contributor to Alzheimer's disease. Studies in mice have shown promising results, with the development of strong antibodies that can slow disease progression and improve cognitive function.
Researchers have identified low levels of naturally occurring antibodies as an increased risk factor for cardiovascular disease, particularly stroke in men. This breakthrough finding suggests that anti-PC antibodies play a crucial role in the development of cardiovascular disease.
Researchers developed an injectable vaccine grown in genetically engineered plants to treat follicular B-cell lymphoma, a chronic and incurable disease. The plant-grown vaccines lack side effects and could allow earlier, more aggressive management of the cancer.
Exhausted B cells hinder HIV-infected individuals' ability to clear the virus from their bodies. Researchers found that these cells produce low-quality antibodies, making it challenging to develop an effective vaccine.
Scientists discovered that HIV depletes functional B cells, which produce antibodies. The fatigued B cells overexpress the protein FCRL4, dampening their response to infection.
Researchers found a strong association between human herpesvirus 8 (HHV-8) infection and ketosis-prone type 2 diabetes mellitus (DM-2) in persons from sub-Saharan Africa. HHV-8 antibodies were present in 87.7% of patients with DM-2, compared to 15.1% of those without the condition.
Scientists at La Jolla Institute for Immunology discovered a previously unknown mechanism in how the body responds to viruses, illuminating a new approach to developing vaccines. The finding reveals that B cells and CD4 T cells recognize the same piece of the virus, narrowing down the search for antigens.
Researchers developed a promising new technique to track genetically engineered cells using antibody fragments as reporter genes, which could advance disease treatment. The technique offers several advantages over existing methods, including improved specificity and accuracy.
Researchers found that a chicken antibody behaves differently from its human counterpart, which sheds light on the origin of allergic reactions. The discovery could lead to designing drugs that alter the interaction between antibodies and white blood cells.
Researchers have developed a chemically modified protein that neutralizes inhibitor antibodies in people with Hemophilia A, offering a potential new treatment option. The modified protein, called electrophilic FVIII analog (E-FVIII), permanently inactivates these antibodies, paving the way for more effective blood clotting correction.
Researchers at the University of New Hampshire Glycomics Center have identified a specific carbohydrate structure that confers anti-inflammatory activity to a glycoprotein antibody. This discovery may lead to improved treatment options for autoimmune diseases such as lupus and rheumatoid arthritis.
Research found that thalassemic patients had a higher prevalence of anti-HAV IgG antibodies than healthy controls. This is unexpected, as previous studies showed lower rates in thalassemics. The study recommends active immunization for transfused thalassemia patients to reduce liver infections.
Researchers at the University of Michigan discovered a link between specific antibodies and oral health, finding that healthy individuals have higher antibody levels to a key protein in periodontal disease. This discovery could lead to improved treatment responses and prevention strategies.
Researchers in Uganda have discovered a new orthopoxvirus in red colobus monkeys, similar to those causing monkeypox and cowpox. The finding highlights the potential for unknown pathogens to emerge in wildlife and pose risks to human health.
Researchers at the University of Illinois have developed a new technique to image cells under an electron microscope, yielding a sharper picture of chromatin structure. This method allows for enhanced staining and structural preservation, enabling scientists to study chromatin packing and gene expression in high resolution.
A simple and fast screening technique has been developed to identify promising synthetic molecules that mimic therapeutic antibodies and can treat cancer at a lower cost. The new method screened over 300,000 peptoids and isolated five candidates that showed promise in treating human tumors.
A study published in Arthritis Research & Therapy found that a gluten-free vegan diet can lower cholesterol and oxidized LDL levels, while raising natural antibodies against phosphorylcholine in patients with rheumatoid arthritis. This may help protect against heart attacks and stroke.
New DNA vaccine data identified in mice shows increased immune response by targeting HIV protein gp41 to DCs with a single-chain Fv antibody. This approach induced stronger T cell responses and protected mice from the virus more efficiently than current DNA vaccines.
New DNA vaccine technology targets DCs for enhanced immune response; studies in mice show improved protection against viruses and potential applications for cystic fibrosis modeling. Genetic manipulation creates large animal models of CF, providing new avenues for disease research.
Researchers at ETH Zurich have developed a novel antibody test that can detect specific antibodies against Plasmodium falciparum's toxic sugar molecules. This test has the potential to protect adults from severe malaria and could also be used to develop a selective vaccine for infants under 5, who are most vulnerable to the disease.
A recent study published in the Journal of Neuroimmunology found that mothers of autistic children may produce antibodies against their fetuses' brain tissue, which can cause changes leading to autism. The study suggests an association between maternal antibody production and developmental regression in children with autism.
Scientists from University of Chicago Medical Center report that moving active genes to nucleus periphery can silence them, preventing transcription. This novel form of gene regulation involves attachment to inner nuclear membrane, blocking transcription through proteins residing on the membrane.
A study by UC-Davis researchers found that antibodies in mothers of children with autism bind to fetal brain cells, potentially disrupting healthy development. The findings suggest a possible link between the maternal immune system and autism risk, paving the way for future research on prenatal identification and prevention.
Researchers found that lower transmission rates increase dengue deaths by reducing the development of immunity to new strains during a critical cross-immunity period. This allows the virus to gain entry into cells and cause more severe infections.
Researchers found that breakdown of self-cleaning mechanism in kidneys can lead to dysfunction and disease. The study suggests that defects in this clearance mechanism can cause accumulation of toxic substances, such as autoimmune antibodies, which can damage the kidney.
Researchers at Yale University found that an antibody used to treat certain cancers and rheumatoid arthritis delays type 1 diabetes in mice. The treatment works by depleting B cells, which can continue to suppress the inflammatory response even after the antibody is no longer administered.
Researchers have identified immunomodulatory anticancer drugs lenalidomide and pomalidomide as effective therapies for inducing fetal hemoglobin production in sickle-cell disease patients. Additionally, a new compound has been discovered to treat protein-losing enteropathy, a condition causing excessive protein loss from the gut.
HIV-infected children in Central Africa show low levels of antibodies to vaccines after childhood immunization. Researchers suggest adapted vaccine schedules may be needed for HIV-exposed infants.
A new vaccine targeting angiotensin II has shown promising results in reducing blood pressure in a small study. The vaccine produced strong antibody responses and significantly lowered systolic and diastolic blood pressures in patients with mild-to-moderate high blood pressure.
Researchers found that ABO-incompatible infant heart transplantation is as safe as transplantation with compatible blood group types. The study suggests that this procedure could significantly reduce the number of infants who die while waiting for a donor heart, with mortality rates potentially decreasing by up to 20%.
Researchers found an antibody against placental growth factor (PlGF) blocks tumor growth and enhances chemotherapy effects in mice. The antibody has a better safety profile than VEGF inhibitors, which cause severe side effects.
Scientists at Newcastle University have developed a technology using UV light to activate antibodies specifically targeting tumour cells. The cloaked antibodies can be used alone or in combination with existing antibodies, minimizing side effects and maximizing destruction of tumours.
Research suggests viruses like Human Ad-36 may play a role in causing obesity in humans, with evidence showing weight gain and fat storage in infected animals. Studies also found connections between viral infections and obesity in human subjects, including exposure to the Ad-36 virus.
David Spiegel, a Yale chemist, has received a $1.5 million NIH Director's New Innovator Award to develop a 'rational' approach for using antibodies to target various cells and diseases. He aims to design DNP-compounds that recognize pathogens and attract anti-DNP antibodies, destroying diseased cells.
Researchers at Duke University Medical Center analyzed 8,300 heart surgery patients and found no association between transfused female plasma and adverse outcomes, even a potential protective effect.
Researchers at Mayo Clinic have discovered an antibody that can repair the damaged myelin sheath in laboratory mouse models, a crucial step towards treating multiple sclerosis and related disorders. The antibody promotes remyelination with a single dose, paving the way for potential new treatments.
Researchers at Saint Louis University have found an injectable antibody that can reverse learning problems in mice with an animal version of Alzheimer's disease. The antibody, part of the IgM class, targets amyloid beta protein and prevents it from becoming toxic.
Researchers at UT Southwestern Medical Center have identified a likely cause of kidney transplant rejection: antibodies attacking MICA antigens. The study found that patients who showed the most marked effect from these antibodies were those considered high-risk for clinical transplantation.
Researchers found that combining Lactobacillus rhamnosus GG probiotic strain with lower doses of hyperimmune bovine colostrum (HBC) provides protection against rotavirus infection, effective as high-dose HBC alone. This combination therapy could help relieve the immense disease burden posed by rotavirus in developing countries.
Researchers have identified radial spoke protein 44 (RSP44) as a key molecule in immune infertility, a condition causing the immune system to attack sperm. The discovery may lead to new diagnostic tools and treatments for this condition, which affects up to 12% of unexplained infertility cases in women.
Researchers discovered that first-degree relatives of PBC patients have a higher prevalence of anti-mitochondrial antibodies, a biomarker indicative of the disease. This finding enables early screening and assessment of high-risk family members through simple blood tests, potentially leading to better outcomes for PBC patients.
Research finds patients with lower levels of HCV antibody titer tend to have a brighter clinical outcome. Co-infection by hepatitis B and A viruses is associated with a higher possibility of self recovery, possibly due to interference with virus replication.
Scientists from around the world present convergent views on the 'memory of water' concept, which suggests that water can display memory effects. Researchers found large-scale structural changes in liquid water, potentially accounting for claims of memory of water effects.